Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16004525 | 1.00 | POLB (0.52) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL17448154 | 0.91 | POLB (0.48) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL21609612 | 0.91 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL21609614 | 0.91 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20924535 | 0.91 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL16156445 | 0.91 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL16156444 | 0.91 | POLB (0.54) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20924349 | 0.86 | POLB (0.56) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20924538 | 0.86 | POLB (0.56) | POLBFUT5P2RY2P2RY4P2RY6 | |
| SCHEMBL20924397 | 0.86 | POLB (0.56) | POLBFUT5P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346310-A1 | Drug formulations | ASTEX PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9381207-B2 | Drug formulations | ASTEX PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160015805-A1 | DRUG COMBINATIONS | ASTEX PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20140303107-A1 | DRUG FORMULATIONS | ASTEX PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2014134355-A1 | DRUG COMBINATIONS | ASTEX PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303107-A1 | DRUG FORMULATIONS | MCL1, DNMT3A, TET2 | POLB 677/4885FUT5 3024/4885P2RY2 4299/4885 |
| US-20160015805-A1 | DRUG COMBINATIONS | TET2, DCTD, TET1 | POLB 785/4885FUT5 2374/4885P2RY2 4163/4885 |
| US-20160346310-A1 | Drug formulations | MCL1, DNMT3A, TET2 | POLB 677/4885FUT5 3024/4885P2RY2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.